Importantly, inhibitors targeting JAK or STAT3 phosphorylation alleviate myeloid expansion, providing a rationale for JAK/STAT pathway inhibition in CMML therapy. This evidence concerns the gene STAT3 and chronic myelomonocytic leukemia.